Palladone (Hydromorphone Hydrochloride)

Hydromorphone hydrochloride, the active ingredient in Palladone, is an opioid analgesic presented as a strength/form for oral use. It treats moderate to severe pain, particularly in patients who require continuous, around‑the‑clock management of cancer‑related or postoperative pain.

GNH USA supplies Palladone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Hydromorphone hydrochloride is an opioid that acts on the central nervous system to relieve pain in several clinical contexts. - Cancer‑related pain: Provides strong analgesia for patients with malignant disease when other opioids are insufficient. - Post‑operative pain: Controls acute pain following major surgical procedures. - Severe chronic non‑cancer pain: Offers long‑term relief for patients with debilitating chronic pain unresponsive to weaker analgesics.

Adverse reactions to hydromorphone may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach and urge to vomit. - Constipation: reduced bowel motility leading to hard stools. - Drowsiness: feeling unusually sleepy or fatigued. - Dizziness: light‑headed sensation, especially when standing quickly. - Dry mouth: reduced salivation causing a parched feeling. - Sweating: increased perspiration without exertion.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure causing faintness. - Cardiac arrhythmias: irregular heart rhythms that may require medical attention. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Dependence and withdrawal: physical dependence developing with prolonged use. - adrenal insufficiency: rare hormonal imbalance affecting stress response.

When prescribing hydromorphone, clinicians should consider several safety measures. - Assess pain severity and prior opioid exposure: ensure appropriate indication before initiating therapy. - Monitor for respiratory depression: especially during dose titration and in opioid‑naïve patients. - Evaluate renal and hepatic function: adjust dosing in patients with impairment. - Avoid concurrent central nervous system depressants: limit additive sedation risk. - Educate patients on constipation management: use laxatives or stool softeners as needed. - Store at ambient temperature: keep below 25°C in the original container, protected from moisture and direct sunlight.

Hydromorphone may interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Benzodiazepines: combined use can cause profound respiratory depression and excessive sedation. - Barbiturates: may potentiate central nervous system depression, increasing overdose risk. - Muscle relaxants: additive sedative effects can impair respiration and cognition.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may increase serotonin levels and risk of serotonin syndrome. - Anticholinergic agents: can exacerbate constipation and urinary retention. - CYP3A4 inhibitors (e.g., ketoconazole): may raise hydromorphone plasma concentrations.